Triple Negative Breast Cancer Clinical Trials in Charleston, South Carolina

5 studies are recruiting for triple negative breast cancer in Charleston, South Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Medical University of South Carolina, Charleston, South Carolina

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

   The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Medical University of South Carolina, Charleston, South Carolina

   Locations

   372 in total

   Run by

   Gilead Sciences

   See if you can join NCT05633654 on ClinicalTrials.gov

3. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MUSC Hollings Cancer Center /ID# 257935, Charleston, South Carolina

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

4. NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

   This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardia…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Medical University of South Carolina, Charleston, South Carolina

   Run by

   Medical University of South Carolina

   See if you can join NCT06845319 on ClinicalTrials.gov

5. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

   This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Medical University of South Carolina, Charleston, South Carolina

   Locations

   15 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04468061 on ClinicalTrials.gov